Vir Biotechnology, Inc. (VIR)
VIR moved a median of -0.18% 30 minutes after news, and -0.30% by the close. How VIR actually reacts to news — the realized, point-in-time move the market made, measured across 351 labeled events over the last three years with zero look-ahead.
VIR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 351 |
| 30-min | -0.18% | 41% | 351 |
| 60-min | -0.17% | 46% | 351 |
| to close | -0.30% | 44% | 351 |
| Middle 50% of VIR reactions | -1.40% to +0.89% |
|---|---|
| Median reaction (30-min) | -0.18% |
| Measured reactions | 351 |
Half of all Vir Biotechnology, Inc. news events land between -1.40% and +0.89% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VIR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 69 | +0.10% | 58% | -0.23% |
| Price-target raises | 13 | -0.38% | 39% | -0.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how VIR ranks against every other measured name →
That’s how VIR usually reacts — get an email when it moves on news →Email me when VIR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VIR's baseline. Nothing else.
Recent VIR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Vir Biotechnology, Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | -4.32% | |
| Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors | Press release | Business Wire | -0.92% | -4.32% | |
| Form 8-K Vir Biotechnology, Inc. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -1.61% | -3.47% | |
| Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer | Press release | Business Wire | -1.61% | -3.47% | |
| Vir Biotechnology Appoints David Liu as Chief Medical Officer | Press release | Business Wire | +1.10% | +1.77% | |
| Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 | Press release | Business Wire | -1.93% | -2.52% | |
| Form 8-K Vir Biotechnology, Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +2.39% | +2.82% | |
| Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer | Press release | Business Wire | +2.39% | +2.82% | |
| Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | Business Wire | +1.11% | +7.68% | |
| Form 10-Q Vir Biotechnology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.02% | -8.60% | |
| Form 8-K Vir Biotechnology, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -3.02% | -8.60% | |
| Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | Business Wire | -3.02% | -8.60% | |
| Form 8-K Vir Biotechnology, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | -3.44% | |
| Vir Biotechnology Announces Chief Financial Officer Transition | Press release | Business Wire | +0.28% | -3.44% | |
| Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results | Press release | Business Wire | +1.25% | +1.41% | |
| Form 8-K Vir Biotechnology, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | +2.53% | |
| Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors | Press release | Business Wire | +0.36% | +2.53% | |
| Form 8-K Vir Biotechnology, Inc. For: May 25 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +5.88% | |
| Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | Press release | Business Wire | -1.45% | -1.84% | |
| Form 10-Q Vir Biotechnology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.81% | -5.89% | |
| Form 8-K Vir Biotechnology, Inc. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.81% | -5.89% | |
| Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | Business Wire | -0.81% | -5.89% | |
| Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference | Press release | Business Wire | +0.59% | +1.98% | |
| Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results | Press release | Business Wire | -1.42% | -2.08% | |
| Form ARS Vir Biotechnology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +1.42% | |
| Form DEF 14A Vir Biotechnology, Inc. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -0.38% | -1.62% | |
| Form DEFA14A Vir Biotechnology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.38% | -1.62% | |
| Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer | Press release | Business Wire | -0.38% | -1.62% | |
| Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer | Press release | Business Wire | +2.08% | +1.97% | |
| Form 8-K Vir Biotechnology, Inc. For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +2.08% | +1.97% | |
| Form 8-K Vir Biotechnology, Inc. For: Mar 04 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -1.83% | |
| Form 8-K Vir Biotechnology, Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +3.73% | +5.54% | |
| Form 8-K Vir Biotechnology, Inc. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +1.13% | -2.15% | |
| Vir Biotechnology to Participate in Upcoming Investor Conferences | Press release | Business Wire | +1.13% | -2.15% | |
| Vir Biotechnology Announces Pricing of Public Offering of Common Stock | Press release | Business Wire | -0.90% | +4.48% | |
| Biotech and Big Tech Drive the Morning Narrative | Press release | GlobeNewswire | +0.99% | -0.89% | |
| Vir Biotechnology Announces Proposed Public Offering of Common Stock | Press release | Business Wire | +6.72% | +1.83% | |
| Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer | Press release | PR Newswire | -4.29% | -4.14% | |
| Form 10-K Vir Biotechnology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.29% | -4.14% | |
| Form 8-K Vir Biotechnology, Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | -4.29% | -4.14% | |
| Form S-8 Vir Biotechnology, Inc. | SEC filing · Form S-8 | SEC EDGAR | -4.29% | -4.14% | |
| Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | -4.29% | -4.14% | |
| Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer | Press release | Business Wire | -4.29% | -4.14% | |
| Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +0.28% | +3.59% | |
| Form 8-K Vir Biotechnology, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.10% | +0.51% | |
| Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones | Press release | Business Wire | -1.10% | +0.51% | |
| Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +1.13% | +3.65% | |
| Form 8-K Vir Biotechnology, Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +2.37% | -5.97% | |
| Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program | Press release | Business Wire | +2.37% | -5.97% | |
| Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference | Press release | Business Wire | +1.26% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VIR section they belong to.
Where else VIR is measured.
VIR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Vir Biotechnology, Inc.'s median reaction calculated?
Every labeled VIR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 351 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of VIR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VIR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.